A Phase I Trial of Etoposide and Topotecan for Solid Tumors
Author Information
Author(s): Penson R T, Seiden M V, Matulonis U A, Appleman L J, Fuller A F Jr, Goodman A, Campos S M, Clark J W, Roche M, Eder J P Jr
Primary Institution: Massachusetts General Hospital
Hypothesis
Can a novel schedule of oral etoposide and infusional topotecan improve treatment outcomes in patients with refractory solid tumors?
Conclusion
The study found that the alternating schedule of etoposide and topotecan was well tolerated and showed promising clinical activity.
Supporting Evidence
- 36 patients were enrolled in the study.
- 18% of patients had a confirmed response to treatment.
- 56% of patients showed either a response or stable disease.
- The treatment was well tolerated with only modest toxicity.
Takeaway
This study tested a new way to give two cancer drugs together, and it worked pretty well for some patients without making them too sick.
Methodology
Patients received alternating doses of oral etoposide and infusional topotecan over 12 weeks, with dose adjustments based on toxicity.
Limitations
The study was limited by a small sample size and the specific patient population, which may not be generalizable.
Participant Demographics
Median age was 57 years, with a range of 22 to 78 years; most patients had ovarian cancer.
Statistical Information
Confidence Interval
95% CI: 6–31%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website